To determine the rate of achieving The Lupus Low Disease Activity State (LLDAS) in children with systemic lupus erythematosus (SLE) for tracing pertinent treatment modalities.
Methods
A total of 122 juvenile-onset SLE (jSLE) patients from six pediatric rheumatology centers in Turkey were enrolled in the study. LLDAS-50 was defined as encountering LLDAS for at least 50% of the observation time. According to the achievement of LLDAS-50, clinical features, immunological profiles, and treatments of patients with jSLE have been revealed.
Results
LLDAS of any duration was achieved by 82% of the cohort. Although only 10.8% of the patients achieved remission, 68.9% reached LLDAS-50. A significant difference was found between patients who reached LLDAS-50 and those who did not, in terms of the time to reach low-dose corticosteroid treatment (p = 0.002), the presence of subacute cutaneous findings (p = 0.007), and the presence of proteinuria (p = 0.002). Both of the groups were under similar treatment approaches. However, the number of patients being treated with corticosteroids at the last visit was found to be significantly higher in patients who achieved LLDAS-50 (p<0.001).
Conclusion
Targeting LLDAS in jSLE, even with long-term, low-dose corticosteroid use, seems to be an achievable goal in clinical practice.
SmithEMDLythgoeHMidgleyA, et al. Juvenile-onset systemic lupus erythematosus: update on clinical presentation, pathophysiology and treatment options. Clin Immunol2019; 209: 108274. DOI: 10.1016/j.clim.2019.108274.
2.
LivingstonBBonnerAPopeJ. Differences in clinical manifestations between childhood-onset lupus and adult-onset lupus: a meta-analysis. Lupus2011; 20: 1345–1355.
3.
LivingstonBBonnerAPopeJ. Differences in autoantibody profiles and disease activity and damage scores between childhood- and adult-onset systemic lupus erythematosus: a meta-analysis. Semin Arthritis Rheum2012; 42: 271–280.
4.
Artim-EsenBŞahinSÇeneE, et al. Comparison of disease characteristics, organ damage, and survival in patients with juvenile-onset and adult-onset systemic lupus erythematosus in a combined cohort from 2 tertiary centers in Turkey. J Rheumatol 2017 May; 44(5): 619–625. DOI: 10.3899/jrheum.160340.
5.
SwartJFvan DijkhuizenEHPWulffraatNM, et al. Clinical Juvenile Arthritis Disease Activity Score proves to be a useful tool in treat-to-target therapy in juvenile idiopathic arthritis. Ann Rheum Dis 2018 Mar; 77(3): 336–342. DOI: 10.1136/annrheumdis-2017-212104.
6.
SteimanAJUrowitzMBIbañezD, et al. Prolonged clinical remission in patients with systemic lupus erythematosus. J Rheumatol 2014 Sep; 41(9): 1808–1816. DOI: 10.3899/jrheum.131137.
7.
FranklynKLauCSNavarraSV, et al. Definition and initial validation of a Lupus Low Disease Activity State (LLDAS). Ann Rheum Dis 2016 Sep; 75(9): 1615–1621. DOI: 10.1136/annrheumdis-2015-207726.
8.
FanouriakisAKostopoulouMAlunnoA, et al. 2019 update of the EULAR recommendations for the management of systemic lupus erythematosus. Ann Rheum Dis2019; 78(6): 736–745. DOI: 10.1136/annrheumdis-2019-215089.
9.
ZenMIaccarinoLGattoM, et al. Lupus low disease activity state is associated with a decrease in damage progression in Caucasian patients with SLE, but overlaps with remission. Ann Rheum Dis 2018 Jan; 77(1): 104–110. DOI: 10.1136/annrheumdis-2017-211613.
10.
PetriMMagderLS. Comparison of remission and Lupus Low Disease Activity State in damage prevention in a United States systemic lupus erythematosus cohort. Arthritis Rheumatol2018; 70: 1790–1795.
11.
Tsang-A-SjoeMWPBultinkIEMHeslingaM, et al. Both prolonged remission and Lupus Low Disease Activity State are associated with reduced damage accrual in systemic lupus erythematosus. Rheumatology2017; 56: 121–128.
12.
SharmaCRaymondWEilertsenG, et al. Association of achieving lupus low disease activity state fifty percent of the time with both reduced damage accrual and mortality in patients with systemic lupus erythematosus. Arthritis Care Res2020; 72: 447–451. DOI: 10.1002/acr.23867
13.
TaniCVagelliRStagnaroC, et al. Remission and low disease activity in systemic lupus erythematosus: an achievable goal even with fewer steroids? Real-life data from a monocentric cohort. Lupus Sci Med2018; 5: e000234.
14.
SozeriBSönmezHEDemirF, et al.Time to collaborate: objectives, design, and methodology of PeRA-research group. North Clin Istanbul2020, Epub ahead of print. DOI: 10.14744/nci.2020.25826.
15.
PetriMOrbaiAMAlarcónGS, et al. Derivation and validation of the Systemic Lupus International Collaborating Clinics classification criteria for systemic lupus erythematosus. Arthritis Rheumatism2012; 64: 2677–2686.
16.
HochbergMC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum1997; 40: 1725–1725.
Gutiérrez-SuárezRRupertoNGastaldiR, et al. A proposal for a pediatric version of the Systemic Lupus International Collaborating Clinics/American College of Rheumatology Damage Index based on the analysis of 1,015 patients with juvenile-onset systemic lupus erythematosus. Arthritis Rheum 2006 Sep; 54(9): 2989–2996. DOI: 10.1002/art.22048.
19.
WatsonLLeoneVPilkingtonC, et al. Disease activity, severity, and damage in the UK juvenile-onset systemic lupus erythematosus cohort. Arthritis Rheum 2012 Jul; 64(7): 2356–2365. DOI: 10.1002/art.34410.
20.
AmbroseNMorganTAGallowayJ, et al. Differences in disease phenotype and severity in SLE across age groups. Lupus 2016 Dec; 25(14): 1542–1550. DOI: 10.1177/0961203316644333.
21.
GolderVKandane-RathnavakeRKandane-RathnayakeR, et al. Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohort. Arthritis Res Ther2016; 18: 260.
22.
BabaogluHLiJGoldmanD, et al. Predictors of predominant lupus low disease activity state (LLDAS-50). Lupus 2019 Dec; 28(14): 1648–1655. DOI: 10.1177/0961203319886028.
23.
SteimanAJGladmanDDIbañezD, et al. Prolonged serologically active clinically quiescent systemic lupus erythematosus: frequency and outcome. J Rheumatol2010; 37(9): 1822–1827. DOI: 10.3899/jrheum.100007.
24.
MathianAPhaMHarocheJ, et al. Withdrawal of low-dose prednisone in SLE patients with a clinically quiescent disease for more than 1 year: a randomised clinical trial. Ann Rheum Dis 2020 Mar; 79(3): 339–346. DOI: 10.1136/annrheumdis-2019-216303.
25.
WalshMMerkelPAMahrA, et al. Effects of duration of glucocorticoid therapy on relapse rate in antineutrophil cytoplasmic antibody-associated vasculitis: a meta-analysis. Arthritis Care Res 2010 Aug; 62(8): 1166–1173. DOI: 10.1002/acr.20176.
26.
Costedoat-ChalumeauNGalicierLAumaîtreO, et al. Hydroxychloroquine in systemic lupus erythematosus: results of a French multicentre controlled trial (PLUS study). Ann Rheum Dis2013; 72(11): 1786–1792.
27.
ShinjoSKBonfáEWojdylaD, et al. Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum2010; 62(3): 855–862.
